Q2 2026 saw 6.6% sales growth to $25.3B and adjusted EPS up 4.7% to $2.90, driven by innovation and strong performance in Innovative Medicine and MedTech. Full-year guidance was raised, with operational sales growth expected at 6.8% and key pipeline milestones ahead.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.